Dmitrij Hristodorov

Aachen, NW 52074, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment.

Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment.

Journal: Progress in retinal and eye research

Published: October 31, 2023

Human MAP Tau Based Targeted Cytolytic Fusion Proteins.

Human MAP Tau Based Targeted Cytolytic Fusion Proteins.

Journal: Biomedicines

Published: April 21, 2017

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.

Journal: Oncotarget

Published: March 14, 2016

Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.

Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.

Journal: Cancer letters

Published: November 18, 2015

A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.

A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.

Journal: International journal of cancer

Published: September 04, 2015

Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.

Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.

Journal: Immunology and cell biology

Published: August 16, 2015

Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.

Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.

Journal: mAbs

Published: July 29, 2015

The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.

The Fc-alpha receptor is a new target antigen for immunotherapy of myeloid leukemia.

Journal: International journal of cancer

Published: January 30, 2015

Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.

Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.

Journal: mAbs

Published: December 18, 2014

Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.

Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.

Journal: Cancer letters

Published: October 30, 2014

EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.

EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.

Journal: Molecular cancer therapeutics

Published: July 02, 2014

Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.

Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.

Journal: British journal of haematology

Published: August 21, 2013

Showing 1-12 of 17

Last Updated: 09/26/2026